Structure via PubChem · Public domain (PubChem)
eptifibatide
Sign in to saveAlso known as C68-22, S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide], N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein () found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginine-glycine-aspartate-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-p
Chemical data
- Formula
- C35H49N11O9S2
- Molecular weight
- 832 g/mol
- IUPAC name
- 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
- SMILES
- C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
- InChIKey
- CZKPOZZJODAYPZ-LROMGURASA-N
- XLogP
- -2.4
- Polar surface area
- 377 Ų
- H-bond donors
- 10
- H-bond acceptors
- 12
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 1998
- Admin. routes
- parenteral
- Indications
- myocardial infarction, Recurrent thrombophlebitis, cardiovascular disease, acute coronary syndrome
via ChEMBL · EBI
Research
1,352 papersvia PubMed
Wikidata facts
- Mass
- 831.316
- Has use
- medication
Show 10 more facts
- chemical formula
- C₃₅H₄₉N₁₁O₉S₂
- World Health Organisation international non-proprietary name
- eptifibatide
- medical condition treated
- ischemia
- canonical SMILES
- C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
- isomeric SMILES
- C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
- defined daily dose
- 0.2
- subject has role
- platelet aggregation inhibitors
- has characteristic
- biopharmaceutical
- physically interacts with
- Integrin subunit beta 3
- significant drug interaction
- alteplase
Sources (7)
via Wikidata · CC0
~6 min read
Encyclopedic overview
9 sectionsContents
- Indications
- Contraindications and precautions
- Side effects
- Study results
- Additional information
- Inventors
- See also
- References
- External links
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein () found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginine-glycine-aspartate-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
==Indications==
Excerpted from Wikipedia’s “eptifibatide” article, available under the CC BY-SA 4.0 licence.